Table 1.
Demographic and clinical characteristics of patients with endometrioma.
| Demographic or characteristic | No. of patients | % |
|---|---|---|
| Age (years), (M ± SD) | 32.63 ± 0.29 | |
| BMI (kg/m2), (M ± SD) | 21.00 ± 0.14 | |
| Complaint, n (%) | ||
| Ultrasound-cyst | 259 | 80.2 |
| Dysmenorrhea | 16 | 5.0 |
| Dysmenorrhea-heavy | 18 | 5.6 |
| Infertility | 12 | 3.7 |
| Other symptoms | 18 | 5.6 |
| Parity, n (%) | ||
| ≥1 | 98 | 30.3 |
| Infertility, n (%) | ||
| Primary infertility | 39 | 12.1 |
| Second infertility | 22 | 6.8 |
| Dysmenorrhea, n (%) | ||
| Mild (VAS 1–4) | 44 | 13.6 |
| Moderate-heavy (VAS 5–10) | 208 | 64.4 |
| Chronic pelvic pain, n (%) | 54 | 16.7 |
| CA125 [n (%)] | ||
| ≤ 35 IU/ml | 85 | 26.3 |
| >35 IU/ml | 238 | 73.7 |
| Prior endometrioma surgery, n (%) | 16 | 5 |
| Preoperative GnRH-a treatment, n (%) | 70 | 21.7 |
| Endometrial cyst localization, n (%) | ||
| Left ovary | 94 | 29.1 |
| Right ovary | 80 | 24.8 |
| Both side | 149 | 46.1 |
| Sum of cyst diameters, n (%) | ||
| ≤ 10 cm | 244 | 75.7 |
| >10 cm | 79 | 24.5 |
| Deep endometriosis, n (%) | 177 | 54.8 |
| Uterine fibroids, n (%) | 57 | 17.6 |
| Adenomyosis, n (%) | 128 | 39.6 |
| r-ASRM stage, n (%) | ||
| I | 1 | 0.3 |
| II | 8 | 2.5 |
| III | 102 | 31.6 |
| IV | 212 | 65.6 |
| Postoperative treatment | ||
| COCs, n (%) | 12 | 3.7 |
| COCs duration (months), median (IQR) | 6 (4.5–12) | |
| LNG-IUD, n (%) | 13 | 4.0 |
| GnRH-a, n (%) | 236 | 73.1 |
| GnRH-a + LNG-IUD, n (%) | 62 | 19.2 |
| GnRH-a duration (months), median (IQR) | 3 (3–3) | |
| LNG-IUD duration (months), median (IQR) | 60 (45.75–60.0) | |
| Postoperative pregnancy, n (%) | ||
| Natural pregnancy | 104 | 32.2 |
| Assisted reproductive technology | 25 | 7.7 |
| Natural abortion | 3 | 0.9 |
| Follow-up time (months), median (IQR) | 84 (72–96) | |
| Recurrence, n (%) | ||
| Ultrasound-Endometrioma | 21 | 6.5 |
| Endometriosis related pain | 34 | 10.5 |
| Both | 10 | 3.1 |
M ± SD, Mean and standard deviation; BMI, Body mass index; VAS, Visual Analog Scale; GnRH-a, Gonadotropin-releasing hormone agonist; r-ASRM, American Society for Reproductive Medicine revised staging system; IQR, Interquartile range; COCs, Combined oral contraceptives; LNG-IUD, Levonorgestrel-releasing intrauterine device.